Physiology

Herbal medicinal product: Curcumae longae rhizomaArray, C: ongoing call for scientific data

Retrieved on: 
Wednesday, April 3, 2024

Overview

Key Points: 
  • Overview
    This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of turmeric.
  • The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing turmeric.
  • Herbal medicines containing these turmeric preparations are usually available as herbal tea to be drunk and in solid or liquid forms to be taken by mouth.
  • Turmeric preparations may also be found in combination with other herbal substances in some herbal medicines.

Herbal medicinal product: Cynarae foliumArray,Array, C: ongoing call for scientific data

Retrieved on: 
Wednesday, April 3, 2024

Herbal medicinal product: Cynarae foliumArray,Array, C: ongoing call for scientific data

Key Points: 


Herbal medicinal product: Cynarae foliumArray,Array, C: ongoing call for scientific data

Menstrual health literacy is alarmingly low – what you don’t know can harm you

Retrieved on: 
Wednesday, March 13, 2024

When I ask my menstrual health workshop participants – including clinicians – there’s usually a lot of shrugging and shaking of heads.

Key Points: 
  • When I ask my menstrual health workshop participants – including clinicians – there’s usually a lot of shrugging and shaking of heads.
  • If given multiple choice options, most think that periods either “clean the womb” or somehow “help prepare for pregnancy”.
  • Yes, the blood part can stain clothing, but there is nothing pathological, contaminating, or dangerous about periods.

So, why do we have periods?

  • Periods likely evolved as a kind of preemptive abortion, to protect women from unviable or dangerous pregnancies.
  • As a result, we have low rates of conception, high rates of miscarriage, and extremely high rates of maternal mortality in comparison to other mammals.
  • The menstrual cycle is critical for facilitation of the initial steps of this raison d’être of the female reproductive system.
  • The menstrual cycle is critical for facilitation of the initial steps of this raison d’être of the female reproductive system.

What else don’t we know?

  • Perhaps with the fact that the second phase of the cycle from ovulation to menstruation is a series of highly inflammatory processes.
  • This was only very briefly mentioned in three out of 16 textbooks.
  • We really ought to be taught from puberty how to reduce period pain and blood loss – this is not difficult science.

Why aren’t we taught this stuff?

  • My research shows that the exclusive focus on the female sex hormones in menstrual education is informed by societal influences, such as the myth of the hysterical or hormonal female.
  • This gender myth is still alive and well, although now we tend to blame the (female sex) hormones.
  • Again, there was no scientific reason for this change in focus, although it reflected existing societal beliefs about the inherently irrational behaviour of women.
  • Unfortunately, menstrual health literacy has not yet recovered from this shift in physiological models.

So what?

  • It also becomes much easier to differentiate premenstrual changes from underlying health conditions, since the latter will not be substantially alleviated by anti-inflammatory interventions alone.
  • Teaching the reductive hormonal model of the menstrual cycle unintentionally provides pseudo-scientific evidence for the damaging hormonal or hysterical female gender myth.


Sally King is the founder of Menstrual Matters- the world's first evidence-based info hub on menstrual health and rights www.menstrual-matters.com. Her doctoral research and current research fellowship were funded by the ESRC (Economic and Social Research Council).

Affluent Medical : Excellent valve performance at 1 year follow up and rising recognition of Epygon biomimetic mitral valve.

Retrieved on: 
Wednesday, March 13, 2024

Affluent Medical : Excellent valve performance at 1 year follow up and rising recognition of Epygon biomimetic mitral valve.

Key Points: 
  • Affluent Medical : Excellent valve performance at 1 year follow up and rising recognition of Epygon biomimetic mitral valve.
  • The article summarizes the procedure and the follow up at 6 months, which showed continued good prosthetic performance.
  • Examination through a transesophageal echocardiogram revealed excellent valve performance, with neither mitral regurgitation nor paravalvular leak.
  • Mitral valve regurgitation is a serious and potentially fatal disease affecting 2% of the world's population, or approximately 160 million people.

SkinCure Oncology Unveils New Skin Cancer Treatment Technology at American Academy of Dermatology Annual Meeting in San Diego March 8-12 Booth 3555

Retrieved on: 
Thursday, March 7, 2024

GentleView™ is a laser-based imaging device being developed to offer hybrid reflective confocal microscopy and photoacoustic imaging.

Key Points: 
  • GentleView™ is a laser-based imaging device being developed to offer hybrid reflective confocal microscopy and photoacoustic imaging.
  • Reflective confocal microscopy, or RCM, will provide high resolution imaging of the epidermis, to a depth of 200 microns, for cellular level visualization of skin cancer lesions.
  • “SkinCure Oncology,” Brandt continued, “is helping dermatologists nationwide implement the GentleCure Experience – an advanced, noninvasive treatment for NMSC.
  • “Our new devices, subject to FDA Clearance,” Brandt said, “will offer cutting-edge technology in line with SkinCure Oncology’s vision for the future of dermatology.

Where Humanity Meets Technology

Retrieved on: 
Wednesday, February 21, 2024

Dr. Poppy Crum , an eminent neuroscientist, is coming to INVENTURE$ 2024 (Inventures) to talk about these very things.

Key Points: 
  • Dr. Poppy Crum , an eminent neuroscientist, is coming to INVENTURE$ 2024 (Inventures) to talk about these very things.
  • She will be taking the main stage on Friday May 31, 2024 to deliver a keynote address called the Intersection of Humanity and Technology.
  • “I can’t think of a better way to conclude Inventures 2024, than for Dr. Poppy Crum to share her insights about the collision between humanity and technology.
  • Launched in 2018, Inventures is gaining global interest as the place to discover new technologies, talent, capital, customers and markets.

Herbal medicinal product: Silybi mariani fructusArray, F: Assessment finalised

Retrieved on: 
Tuesday, March 12, 2024

Herbal medicinal product: Silybi mariani fructusArray, F: Assessment finalised

Key Points: 


Herbal medicinal product: Silybi mariani fructusArray, F: Assessment finalised

WhiteSwell Announces Six-month Outcomes After eLym System Treatment for Acute Decompensated Heart Failure Patients in its DELTA-HF Study

Retrieved on: 
Wednesday, March 6, 2024

WhiteSwell, a company pioneering a new paradigm in the treatment of acute decompensated heart failure (ADHF), announced today positive six-month follow-up data on the initial nine patients treated in its ongoing DELTA-HF trial evaluating the WhiteSwell eLym™ System.

Key Points: 
  • WhiteSwell, a company pioneering a new paradigm in the treatment of acute decompensated heart failure (ADHF), announced today positive six-month follow-up data on the initial nine patients treated in its ongoing DELTA-HF trial evaluating the WhiteSwell eLym™ System.
  • Nine hospitalized patients with ADHF received eLym therapy in conjunction with diuretic therapy and were followed for six months.
  • Reduced rehospitalizations: Comparing patients’ clinical course before and after eLym therapy, in the six months prior to eLym therapy there were 13 heart failure related hospitalizations, while in the six months after eLym therapy there were just two heart failure hospitalizations and one heart failure related death, for a 77% reduction.
  • The minimally invasive catheter system was successfully deployed and removed in all patients, with a mean treatment time of 24 hours.

LinusBio Named “Fierce 15” Company of 2023 by Fierce Medtech

Retrieved on: 
Tuesday, March 5, 2024

LinusBio , a leader in precision exposome sequencing, today announced its inclusion in Fierce Medtech's "Fierce 15" list for 2023 .

Key Points: 
  • LinusBio , a leader in precision exposome sequencing, today announced its inclusion in Fierce Medtech's "Fierce 15" list for 2023 .
  • This annual special report highlights the most innovative private medtech companies that are making significant strides in the industry.
  • "We are deeply honored and humbled by this highly-regarded recognition," said Manish Arora, PhD, CEO and co-founder of LinusBio.
  • “These companies exemplify the ability of the medtech industry to turn cutting-edge ideas into meaningful outcomes and make them accessible on a large scale.”

Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference

Retrieved on: 
Wednesday, February 28, 2024

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on EDG-5506, an investigational therapy designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies, at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference.

Key Points: 
  • Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on EDG-5506, an investigational therapy designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies, at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference.
  • The conference will take place at the Hilton Orlando in Orlando, FL from March 3-6, 2024.
  • Posters will be showcased during the Networking & Poster Reception in the Exhibit Hall on Monday, March 4, 2024, from 6 – 8 PM ET.
  • The Edgewise presentation and posters will be available on the Edgewise website when they are presented.